| Similar Articles |
|---|
 |
The Motley Fool
April 30, 2008
Brian Lawler |
Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials.   |
The Motley Fool
April 2, 2007
Brian Lawler |
A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note. |
The Motley Fool
April 2, 2008
Brian Lawler |
Alexza Establishes a Cash Pipeline Alexza Pharmaceuticals announces that it has signed a deal that will provide it with up to $50 million over the next two years. Investors take note. |
The Motley Fool
December 29, 2006
Brian Lawler |
No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year. |
The Motley Fool
December 28, 2007
Brian Lawler |
Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug. |
The Motley Fool
October 11, 2010
Travis Hoium |
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
June 8, 2007
Brian Lawler |
A Conversation With Alexza An interview with Alexza Pharmaceuticals' president and CEO on the company's technology and drug pipeline. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
September 21, 2007
Brian Lawler |
Alexza Advances The pharmaceutical company's schizophrenia drug is ready for phase 3 testing, which will begin in the first quarter of 2008. Investors, take note. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
May 28, 2008
Brian Lawler |
Discovery's Costly Debt Delay Discovery Labs announces a new financing agreement, but it's an expensive arrangement. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
April 11, 2007
Brian Lawler |
Get Rich With These Guys Regardless of what type of long-term investment strategy you use, finding companies created under the auspices of proven entrepreneurs such as Moll, Zaffaroni, and Mann and then sticking with them for the long run is one path to investing riches. |
